Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
SYNTHESIS AND COMPOSITION OF RAPAFUCIN LIBRARIES
Document Type and Number:
WIPO Patent Application WO/2017/136708
Kind Code:
A1
Abstract:
A Rapafucin library containing compounds of the general structure, (A) and (E), and a synthesis of these compounds are provided.

Inventors:
LIU JUN (US)
WANG JINGXIN (US)
GUO ZUFENG (US)
HONG SAM (US)
LIU WUKUN (US)
PENG HANJING (US)
DAS MANISHA (US)
Application Number:
PCT/US2017/016481
Publication Date:
August 10, 2017
Filing Date:
February 03, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV JOHNS HOPKINS (US)
International Classes:
C07K17/08; G01N33/566
Domestic Patent References:
WO2010004304A12010-01-14
WO2014201405A12014-12-18
Foreign References:
US20140073581A12014-03-13
US20080306098A12008-12-11
US20090253732A12009-10-08
US6984635B12006-01-10
US20150018340A12015-01-15
US5527907A1996-06-18
US20020052410A12002-05-02
US20140073581A12014-03-13
Other References:
See also references of EP 3411413A4
Attorney, Agent or Firm:
HAILE, Lisa, A. et al. (US)
Download PDF:
View/Download PDF      PDF Help
Claims:
CLAIMS What is claimed is:

1. A compound of Formula I:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

or

wherein R1, R2, R3, R4, and R5 are each independently selected from hydrogen, hydroxyl, alkoxy,

cyano, alkylthio, amino, and alkylamino, is a resin;

wherein one, two, three, or four of A1, A2, A3, A4, and A5 is N or P with the remaining being CH;

wherein one, two, three, or four of B1, B2, B3 and B4 is O, N, or S with the remaining being CH or CH2 as appropriate;

wherein is a single or double bond;

6;

W is O, CH, CH2, CR9, or C R10R11;

L1 and L2 are each independently a direct bond, substituted or unsubstituted -(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nO(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nC(O)(C1- C6)alkyl-, substituted or unsubstituted -(CH2)nC(O)O(C1-C6)alkyl-, substituted or unsubstituted - (CH2)nOC(O)(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nNH(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nC(O)NH(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nS(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C1-C6)alkyl-, substituted or unsubstituted -(C2- C6)alkenyl-, substituted or unsubstituted -(CH2)nO(C2-C6)alkenyl-, substituted or unsubstituted - (CH2)nC(O)(C2-C6)alkenyl-, substituted or unsubstituted -(CH2)nC(O)O(C2-C6)alkenyl-, substituted or unsubstituted -(CH2)nOC(O)(C2-C6)alkenyl-, substituted or unsubstituted - (CH2)nNH(C2-C6)alkenyl-, substituted or unsubstituted -(CH2)nC(O)NH(C2-C6)alkenyl-, substituted or unsubstituted -(CH2)nS(C2-C6)alkenyl-, substituted or unsubstituted - (CH2)nC(O)(CH2)nS(C2-C6)alkenyl-, substituted or unsubstituted -(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nO(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nC(O)(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nC(O)O(C2-C6)alkynyl-, substituted or unsubstituted - (CH2)nOC(O)(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nNH(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nC(O)NH(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nS(C2- C6)alkynyl-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C2-C6)alkynyl-, substituted or unsubstituted -(C1-C6)alkyl- NR18-, substituted or unsubstituted -(CH2)nO(C1-C6)alkyl- NR18-, substituted or unsubstituted -(CH2)nC(O)(C1-C6)alkyl- NR18-, substituted or unsubstituted - (CH2)nC(O)O(C1-C6)alkyl- NR18-, substituted or unsubstituted -(CH2)nOC(O)(C1-C6)alkyl- NR18-, substituted or unsubstituted -(CH2)nNH(C1-C6)alkyl- NR18-, substituted or unsubstituted - (CH2)nC(O)NH(C1-C6)alkyl- NR18-, substituted or unsubstituted -(CH2)nS(C1-C6)alkyl- NR18-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C1-C6)alkyl- NR18-, substituted or unsubstituted -(C2-C6)alkenyl- NR18-, substituted or unsubstituted -(CH2)nO(C2-C6)alkenyl- NR18-, substituted or unsubstituted -(CH2)nC(O)(C2-C6)alkenyl- NR18-, substituted or unsubstituted -(CH2)nC(O)O(C2- C6)alkenyl- NR18-, substituted or unsubstituted -(CH2)nOC(O)(C2-C6)alkenyl- NR18-, substituted or unsubstituted -(CH2)nNH(C2-C6)alkenyl- NR18-, substituted or unsubstituted - (CH2)nC(O)NH(C2-C6)alkenyl- NR18-, substituted or unsubstituted -(CH2)nS(C2-C6)alkenyl- NR18- , substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C2-C6)alkenyl- NR18-, substituted or unsubstituted -(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(CH2)nO(C2-C6)alkynyl- NR18- , substituted or unsubstituted -(CH2)nC(O)(C2-C6)alkynyl- NR18-, substituted or unsubstituted - (CH2)nC(O)O(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(CH2)nOC(O)(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(CH2)nNH(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(CH2)nC(O)NH(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(CH2)nS(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(CH2)nO(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(CH2)nC(O)(C1-C6)alkyl- C(O)-, substituted or unsubstituted - (CH2)nC(O)O(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(CH2)nOC(O)(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(CH2)nNH(C1-C6)alkyl- C(O)-, substituted or unsubstituted - (CH2)nC(O)NH(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(CH2)nS(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(C2-C6)alkenyl- C(O)-, substituted or unsubstituted -(CH2)nO(C2-C6)alkenyl- C(O)-, substituted or unsubstituted -(CH2)nC(O)(C2-C6)alkenyl- C(O)-, substituted or unsubstituted -(CH2)nC(O)O(C2- C6)alkenyl- C(O)-, substituted or unsubstituted -(CH2)nOC(O)(C2-C6)alkenyl- C(O)-, substituted or unsubstituted -(CH2)nNH(C2-C6)alkenyl- C(O)-, substituted or unsubstituted - (CH2)nC(O)NH(C2-C6)alkenyl- C(O)-, substituted or unsubstituted -(CH2)nS(C2-C6)alkenyl- C(O)- , substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C2-C6)alkenyl- C(O)-, substituted or unsubstituted -(C2-C6)alkynyl- C(O)-, substituted or unsubstituted -(CH2)nO(C2-C6)alkynyl- C(O)- , substituted or unsubstituted -(CH2)nC(O)(C2-C6)alkynyl- C(O)-, substituted or unsubstituted - (CH2)nC(O)O(C2-C6)alkynyl- C(O)-, substituted or unsubstituted -(CH2)nOC(O)(C2-C6)alkynyl- C(O)-, substituted or unsubstituted -(CH2)nNH(C2-C6)alkynyl- C(O)-, substituted or unsubstituted -(CH2)nC(O)NH(C2-C6)alkynyl- C(O)-, substituted or unsubstituted -(CH2)nS(C2-C6)alkynyl- C(O)-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C2-C6)alkynyl- C(O)-, -O-, -NH-, -S-, - S(O)-, -SO2-, -Si-, and -B-, wherein each alkyl, alkenyl, and alkynyl group may be optionally substituted with alkyl, alkoxy, amino, hydroxyl, sulfhydryl, halogen, carboxyl, oxo, cyano, nitro, or trifluoromethyl;

L3 is a direct bond, substituted or unsubstituted -(C1-C6)alkyl-, substituted or unsubstituted - (CH2)nO(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nC(O)(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nC(O)O(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nOC(O)(C1- C6)alkyl-, substituted or unsubstituted -(CH2)nNH(C1-C6)alkyl-, substituted or unsubstituted - (CH2)nC(O)NH(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nS(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C1-C6)alkyl-, substituted or unsubstituted -(C2-C6)alkenyl-, substituted or unsubstituted -(CH2)nO(C2-C6)alkenyl-, substituted or unsubstituted - (CH2)nC(O)(C2-C6)alkenyl-, substituted or unsubstituted -(CH2)nC(O)O(C2-C6)alkenyl-, substituted or unsubstituted -(CH2)nOC(O)(C2-C6)alkenyl-, substituted or unsubstituted - (CH2)nNH(C2-C6)alkenyl-, substituted or unsubstituted -(CH2)nC(O)NH(C2-C6)alkenyl-, substituted or unsubstituted -(CH2)nS(C2-C6)alkenyl-, substituted or unsubstituted - (CH2)nC(O)(CH2)nS(C2-C6)alkenyl-, substituted or unsubstituted -(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nO(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nC(O)(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nC(O)O(C2-C6)alkynyl-, substituted or unsubstituted - (CH2)nOC(O)(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nNH(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nC(O)NH(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nS(C2- C6)alkynyl-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C2-C6)alkynyl-, substituted or unsubstituted -(C1-C6)alkyl- NR18-, substituted or unsubstituted -(CH2)nO(C1-C6)alkyl- NR18-, substituted or unsubstituted -(CH2)nC(O)(C1-C6)alkyl- NR18-, substituted or unsubstituted - (CH2)nC(O)O(C1-C6)alkyl- NR18-, substituted or unsubstituted -(CH2)nOC(O)(C1-C6)alkyl- NR18-, substituted or unsubstituted -(CH2)nNH(C1-C6)alkyl- NR18-, substituted or unsubstituted - (CH2)nC(O)NH(C1-C6)alkyl- NR18-, substituted or unsubstituted -(CH2)nS(C1-C6)alkyl- NR18-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C1-C6)alkyl- NR18-, substituted or unsubstituted -(C2-C6)alkenyl- NR18-, substituted or unsubstituted -(CH2)nO(C2-C6)alkenyl- NR18-, substituted or unsubstituted -(CH2)nC(O)(C2-C6)alkenyl- NR18-, substituted or unsubstituted -(CH2)nC(O)O(C2- C6)alkenyl- NR18-, substituted or unsubstituted -(CH2)nOC(O)(C2-C6)alkenyl- NR18-, substituted or unsubstituted -(CH2)nNH(C2-C6)alkenyl- NR18-, substituted or unsubstituted - (CH2)nC(O)NH(C2-C6)alkenyl- NR18-, substituted or unsubstituted -(CH2)nS(C2-C6)alkenyl- NR18- , substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C2-C6)alkenyl- NR18-, substituted or unsubstituted -(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(CH2)nO(C2-C6)alkynyl- NR18- , substituted or unsubstituted -(CH2)nC(O)(C2-C6)alkynyl- NR18-, substituted or unsubstituted - (CH2)nC(O)O(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(CH2)nOC(O)(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(CH2)nNH(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(CH2)nC(O)NH(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(CH2)nS(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C2-C6)alkynyl- NR18-, substituted or unsubstituted -(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(CH2)nO(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(CH2)nC(O)(C1-C6)alkyl- C(O)-, substituted or unsubstituted - (CH2)nC(O)O(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(CH2)nOC(O)(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(CH2)nNH(C1-C6)alkyl- C(O)-, substituted or unsubstituted - (CH2)nC(O)NH(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(CH2)nS(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C1-C6)alkyl- C(O)-, substituted or unsubstituted -(C2-C6)alkenyl- C(O)-, substituted or unsubstituted -(CH2)nO(C2-C6)alkenyl- C(O)-, substituted or unsubstituted -(CH2)nC(O)(C2-C6)alkenyl- C(O)-, substituted or unsubstituted -(CH2)nC(O)O(C2- C6)alkenyl- C(O)-, substituted or unsubstituted -(CH2)nOC(O)(C2-C6)alkenyl- C(O)-, substituted or unsubstituted -(CH2)nNH(C2-C6)alkenyl- C(O)-, substituted or unsubstituted - (CH2)nC(O)NH(C2-C6)alkenyl- C(O)-, substituted or unsubstituted -(CH2)nS(C2-C6)alkenyl- C(O)- , substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C2-C6)alkenyl- C(O)-, substituted or unsubstituted -(C2-C6)alkynyl- C(O)-, substituted or unsubstituted -(CH2)nO(C2-C6)alkynyl- C(O)- , substituted or unsubstituted -(CH2)nC(O)(C2-C6)alkynyl- C(O)-, substituted or unsubstituted - (CH2)nC(O)O(C2-C6)alkynyl- C(O)-, substituted or unsubstituted -(CH2)nOC(O)(C2-C6)alkynyl- C(O)-, substituted or unsubstituted -(CH2)nNH(C2-C6)alkynyl- C(O)-, substituted or unsubstituted -(CH2)nC(O)NH(C2-C6)alkynyl- C(O)-, substituted or unsubstituted -(CH2)nS(C2-C6)alkynyl- C(O)-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C2-C6)alkynyl- C(O)-, wherein each alkyl, alkenyl and alkynyl group may be optionally substituted with alkyl, alkoxy, amino, hydroxyl, sulfhydryl, halogen, carboxyl, oxo, cyano, nitro, or trifluoromethyl;

each m is independently an integer selected from 0, 1, 2, 3, 4, 5, and 6;

each n is independently an integer selected from 0, 1, 2, 3, 4, 5, and 6;

R6 is hyrdrogen or alkyl;

R7 and R8 are each independently selected from hydrogen, hydroxy, alkyl, alkoxy, cyano, alkylthio, amino, and alkylamino, and OPG, wherein OPG is a protecting group;

R9, R10, and R11 are each independently selected from hydrogen, hydroxy, alkyl, alkoxy, cyano, alkylthio, amino, and alkylamino, and OPG, wherein OPG is a protecting group;

wherein the Effector Domain has Formula II:

(II) wherein:

R12, R14, R16, and R18 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted perfluoroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroalkylaryl, (CH2)nCN, (CH2)nCF3, (CH2)nC2F5.

R13, R15, and R17 are each independently the sidechains of naturally occurring amino acids and their modified forms including but are not limited to D-amino acid configuration, or hydrogen, halogen, amino, cyano, nitro, trifluoromethyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted perfluoroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroalkylaryl, substituted or unsubstituted (CH2)n-aryl, substituted or unsubstituted (CH2)n-heteroaryl, (CH2)nCN, (CH2)nCF3, (CH2)nC2F5, (CH2)nOR19, (CH2)nC(O)R19, (CH2)nC(O)OR19, (CH2)nOC(O)R19, (CH2)nNR20R21, (CH2)nC(O)NR20R21, (CH2)nNR22C(O)R19, (CH2)nNR22C(O)OR19, (CH2)nNR22C(O)NR20R21, (CH2)nSR19, (CH2)nS(O)jNR20R21, (CH2)nNR22S(O)jR19, or - (CH2)nNR22S(O)jNR20R21;

R12 and R13, R14 and R15, R16 and R17 can be convalently connected to form a substituted or unsubstituted 5-, 6-, or 7-membered heterocycle.

each k is independently an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

each j is independently an integer selected from 0, 1, and 2;

R19, R20, R21, and R22 are each independently hydrogen, halogen, amino, cyano, nitro, trifluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, alkoxy, alkylamino, alkylthio, aryl, alkylaryl, heteroalkyl, heterocycloalkyl, heteroaryl, or heteroalkylaryl, or R19 and R22 are as described above, and R20 and R21, together with the N atom to which they are attached, form a substituted or unsubstituted 5-, 6-, or 7-membered heterocycloalkyl or a substituted or unsubstituted 5-membered heteroaryl,

wherein each of the above groups listed for R13, R15, and R17 may be optionally independently substituted with 1 to 3 groups selected from halogen, amino, cyano, nitro, trifluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, alkoxy, alkylamino, alkylthio, aryl, alkylaryl, heteroalkyl, heterocycloalkyl, heteroaryl, heteroalkylaryl, (CH2)nCN, (CH2)nCF3, (CH2)nC2F5, (CH2)nOR19, (CH2)nC(O)R19, (CH2)nC(O)OR19, (CH2)nOC(O)R19, (CH2)nNR20R21, (CH2)nC(O)NR20R21, (CH2)nNR22C(O)R19, (CH2)nNR22C(O)OR19, (CH2)nNR22C(O)NR20R21, (CH2)nSR19, (CH2)nS(O)jNR20R21, (CH2)nNR22S(O)jR19, or -(CH2)nNR22S(O)jNR20R21;

or wherein the Effector Domain has Formula III:

wherein:

each k is independently an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

R23 is a hydrogen or alkyl;

X3 is substituted or unsubstituted -(C1-C30)alkyl-, alkenyl-, alkynyl- with each carbon individually assuming one of the following redox states: CH2, CH-OH, C(O);

or wherein the Effector Domain has Formula IV: wherein:

X4 is substituted or unsubstituted -(C1-C30)alkyl-, alkenyl-, alkynyl- with each carbon individually assuming one of the following redox states: CH2, CH-OH, C(O).

Or wherein the Effector Domain has Formula V:

wherein:

R24 and R25 are each a hydrogen or alkyl;

X5 is substituted or unsubstituted -(C1-C30)alkyl-, alkenyl-, alkynyl- with each carbon individually assuming one of the following redox states: CH2, CH-OH, C(O).

Or wherein the Effector Domain has Formula VI: wherein: X6 is substituted or unsubstituted -(C1-C30)alkyl-, alkenyl-, alkynyl- with each carbon individually assuming one of the following redox states: CH2, CH-OH, C(O).

2. The compound of formula I of claim 1, wherein

y

3. The compound of formula I of claim 1, wherein

R is as defined in claim 1 but not wherein R3 is hydrogen, hydroxyl, or OPG, wherein PG is a protecting group, or a resin; wherein R2 is hydrogen, hydroxyl, or alkoxy; and

wherein R1, R4, and R5 are each independently hydrogen or no substituent as dictated by chemical bonding;

wherein is a single or double bond.

4. The compound of formula I of claim 1, wherein

L1 and L2 and the Effector Domain are as defined in claim 1

but L1 and L2 not each independently direct bond, substituted or unsubstituted -(C1- C6)alkyl-, substituted or unsubstituted -(CH2)nO(C1-C6)alkyl-, substituted or unsubstituted - (CH2)nC(O)-, substituted or unsubstituted -(CH2)nC(O)(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nC(O)O(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nNH(C1- C6)alkyl-, substituted or unsubstituted -(CH2)nC(O)NH(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nS(C1-C6)alkyl-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C1- C6)alkyl-, substituted or unsubstituted -(C2-C6)alkenyl-, substituted or unsubstituted - (CH2)nO(C2-C6)alkenyl-, substituted or unsubstituted -(CH2)nC(O)(C2-C6)alkenyl-, substituted or unsubstituted -(CH2)nC(O)O(C2-C6)alkenyl-, substituted or unsubstituted - (CH2)nNH(C1-C6)alkenyl-, substituted or unsubstituted -(CH2)nC(O)NH(C2-C6)alkenyl-, substituted or unsubstituted -(CH2)nS(C2-C6)alkenyl-, substituted or unsubstituted - (CH2)nC(O)(CH2)nS(C2-C6)alkenyl-, substituted or unsubstituted -(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nO(C2-C6)alkynyl-, substituted or unsubstituted - (CH2)nC(O)(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nC(O)O(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nNH(C1-C6)alkynyl-, substituted or unsubstituted - (CH2)nC(O)NH(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nS(C2-C6)alkynyl-, substituted or unsubstituted -(CH2)nC(O)(CH2)nS(C2-C6)alkynyl-, wherein each alkyl, alkenyl, and alkynyl group may be optionally substituted with alkyl, alkoxy, amino, carboxyl, cyano, nitro, or trifluoromethyl;

and the Effector Domain is a compound of Formula VIII

wherein

R12, R14, R14’, R16, and R27 are not each independently hydrogen or alkyl and

R13, R14, R14’, and R16 are not each independently hydrogen, halogen, amino, cyano, nitro, trifluoromethyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted perfluoroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroalkylaryl, (CH2)nCN, (CH2)nCF3, (CH2)nC2F5, (CH2)nOR19, (CH2)nC(O)R19, (CH2)nC(O)OR19, (CH2)nOC(O)R19, (CH2)nNR20R21, (CH2)nC(O)NR20R21, (CH2)nNR22C(O)R19, (CH2)nNR22C(O)OR19, (CH2)nNR22C(O)NR20R21, (CH2)nS(O)jNR20R21, (CH2)nNR22S(O)jR19, or -(CH2)nNR22S(O)jNR20R21;

n is an integer selected from 0, 1, 2, 3, 4, 5, and 6;

j is an integer selected from 0, 1, and 2;

R19, R20, R21, and R22 are each independently hydrogen, halogen, amino, cyano, nitro, trifluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, alkoxy, alkylamino, alkylthio, aryl, alkylaryl, heteroalkyl, heterocycloalkyl, heteroaryl, or heteroalkylaryl, or R19 and R22 are as described above, and R20 and R21, together with the N atom to which they are attached, form a substituted or unsubstituted 5-, 6-, or 7-membered heterocycloalkyl or a substituted or unsubstituted 5-membered heteroaryl,

wherein each of the above groups listed for R13, R15, and R17 may be optionally independently substituted with 1 to 3 groups selected from halogen, amino, cyano, nitro, trifluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, alkoxy, alkylamino, alkylthio, aryl, alkylaryl, heteroalkyl, heterocycloalkyl, heteroaryl, heteroalkylaryl, (CH2)nCN, (CH2)nCF3, (CH2)nC2F5, (CH2)nOR19, (CH2)nC(O)R19, (CH2)nC(O)OR19, (CH2)nOC(O)R19, (CH2)nNR20R21, (CH2)nC(O)NR20R21, (CH2)nNR22C(O)R19, (CH2)nNR22C(O)OR19, (CH2)nNR22C(O)NR20R21, (CH2)nSR19, (CH2)nS(O)jNR20R21, (CH2)nNR22S(O)jR19, or -(CH2)nNR22S(O)jNR20R21.

5. The compound of formula I of claim 1, wherein

L3 is–CH2CH2– ;

R is

R1 , R4, R5 and R6 are each hydrogen;

R2 and R3 are each methoxy;

m = 0;

X2 is O or NR6C(O)

L1 is–CH2-C(O)- or -(CH2)2C(O)-;

L2 is–OCO-CH=CH-(CH2)2N(Me)-; The compound of claim 5, wherein the effector domain of formula II has formula VII Wherein R12, R14, R14’, and R16 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted perfluoroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroalkylaryl, (CH2)nCN, (CH2)nCF3, (CH2)nC2F5.

R13, R15, R15’ and R17 are each independently the sidechains of naturally occurring amino acids and their modified forms including but are not limited to D-amino acid configuration, or hydrogen, halogen, amino, cyano, nitro, trifluoromethyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted perfluoroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroalkylaryl, substituted or unsubstituted (CH2)n-aryl, substituted or unsubstituted (CH2)n-heteroaryl, (CH2)nCN, (CH2)nCF3, (CH2)nC2F5, (CH2)nOR19, (CH2)nC(O)R19, (CH2)nC(O)OR19, (CH2)nOC(O)R19, (CH2)nNR20R21, (CH2)nC(O)NR20R21, (CH2)nNR22C(O)R19, (CH2)nNR22C(O)OR19, (CH2)nNR22C(O)NR20R21, (CH2)nSR19, (CH2)nS(O)jNR20R21, (CH2)nNR22S(O)jR19, or - (CH2)nNR22S(O)jNR20R21.

R12 and R13, R14 and R15, R14’ and R15’, R16 and R17 can be covalently connected to form a substituted or unsubstituted 5-, 6-, or 7-membered heterocycle.

7. The compound of claim 5, wherein the effector domain of formula II has formula VIII -AA1-AA2-AA3-AA4- (VIII)

wherein AA1, AA2, AA3 and AA4 are each independently selected from:

8. The compound of claim 5, wherein

X2 is O and L1 is–CH2-C(O)- .

9. The compound of claim 5, wherein

X2 is NR6C(O) and L1 is -(CH2)2C(O)- .

10. A method for synthesizing a compound or libraries of compounds selected from those described in claim 1 comprising the steps disclosed in the“Detailed Description of the Invention”.

11. A method of using a hybrid cyclic library based on the immunophilin ligand family of natural products FK506 and rapamycin, to screen for compounds for treating cancer.

12. A method of using a hybrid cyclic library based on the immunophilin ligand family of natural products FK506 and rapamycin, to screen for compounds for treating autoimmune disease.
Description:
SYNTHESIS AND COMPOSITION OF RAPAFUCIN LIBRARIES

RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/291,437, filed on February 4, 2016, which is hereby incorporated herein by reference in its entirety.

GRANT INFORMATION

[0002] This invention was made with government support under National Institutes of Health grant DP1CA174428. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION FIELD OF THE INVENTION

[0003] The invention relates generally to hybrid cyclic molecules, and more specifically to hybrid cyclic libraries based on the immunophilin ligand family of natural products FK506 and rapamycyin.

BACKGROUND INFORMATION

[0004] The macrocyclic natural products FK506 and rapamycin are approved immunosuppressive drugs with important biological activities. Both have been shown to inhibit T cell activation, albeit with distinct mechanisms. In addition, rapamycin has been shown to have strong anti-proliferative activity. FK506 and rapamycin share an extraordinary mode of action; they act by recruiting an abundant and ubiquitously expressed cellular protein, the prolyl cis-trans isomerase FKBP, and the binary complexes subsequently bind to and allosterically inhibit their target proteins calcineurin and mTOR, respectively. Structurally, FK506 and rapamycin share a similar FKBP-binding domain but differ in their effector domains. In FK506 and rapamycin, nature has taught us that switching the effector domain of FK506 to that in rapamycin, it is possible to change the targets from calcineurin to mTOR. The generation of a rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.

[0005] With the completion of the sequencing and annotation of the human genome, a complete catalog of all human proteins encoded in the genome is now available. The functions of a majority of these proteins, however, remain unknown. One way to elucidate the functions of these proteins is to find small molecule ligands that specifically bind to the proteins of interest and perturb their biochemical and cellular functions. Thus, a major challenge for chemical biologists today is to discover new small molecule probes for new proteins to facilitate the elucidation of their functions. The recent advance in the development of protein chips has offered an exciting new opportunity to simultaneously screen chemical libraries against nearly the entire human proteome. A single chip, in the form of a glass slide, is sufficient to display an entire proteome in duplicate arrays. Recently, a protein chip with 17,000 human proteins displayed on a single slide has been produced. A major advantage of using human protein chips for screening is that the entire displayed proteome can be interrogated at once in a small volume of assay buffer (<3 mL). Screening of human protein chips, however, is not yet feasible with most, if not all, existing chemical libraries due to the lack of a universal readout for detecting the binding of a ligand to a protein on these chips. While it is possible to add artificial tags to individual compounds in a synthetic library, often the added tags themselves interfere with the activity of ligands. Thus, there remains a need for new compounds and methods for screening chemical libraries against the human proteome.

SUMMARY OF THE INVENTION

[0006] One embodiment of the present invention is to provide a compound of the following structure:

. R 1 and R 3 can independently be any of the following compounds:

R 2 and R 4 can independently be any of the following compounds:

[0007] Another embodiment of the present invention is to provide a compound of the following structure:

R 1 , R 2 , R 3 and R 4 are selected from the same groupings of compounds listed above.

[0008] Another embodiment of the present invention is to provide a compound that includes A15-34-2, A15-39-1, A15-39-2, A15-39-4, A15-39-6, A15-39-8, A15-39-15, A15- 40-2, A15-40-4, A15-40-15, E15-32-2, E15-33-1, E15-33-2, E15-34-1, E15-34-2, E15-39-1, E15-39-2, E15-39-5, E15-40-2, E15-40-4, E15-S-19, E15-S-21, and E15-S-22.

[0009] Another embodiment of the present invention is to provide synthetic methods as outlined in the“Detailed Description of the Invention” for producing a Rapafucin library.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Figure 1. Number of compounds in library. DETAILED DESCRIPTION OF THE INVENTION

EXAMPLE 1

[0011] Scheme 1- Synthetic scheme for Rapafucin molecules containing amide mFKBD

[0012] R 1 and R 3 in Scheme 1 are amino acids selected from the following group of amino acids:

[0013] R 2 and R 4 in Scheme 1 are amino acids selected from the following group of amino acids:

[0014] The synthesis of the amide mFKBD in Scheme 1 is as follows:

[0015] The synthesis of the ether mFKBD in Scheme 1 is as follows:

[0016] The general formula for a Rapafucin with an amide mFKBD is represented by “A”.

[0017] The general formula for a Rapafucin with an ether mFKBD is represented by“E”.

[0018] Specific Examples of“A” and“E” as well as their properties are listed in Table 1.

Table 1 [0019] Approximately, 45,000 compounds were obtained as part of the Rapafucin library (Fig.1).

[0020] Although the invention has been described with reference to the above example, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.

REFERENCES

The following reference is relied upon and incorporated herein in its entirety. 1. US 2014/0073581.




 
Previous Patent: BATTERY COOLING PLATE HEAT EXCHANGER AND PLATE ASSEMBLY

Next Patent: MOLECULAR ASSAYS FOR REGULATING IMMUNOSUPPRESSION, AVERTING IMMUNE-MEDIATED REJECTION AND INCREASING...